Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Huang1, H. Irizar2, R. Kosoy3, W-m. Song3, A. Dinarzo3, K. Hao3, J. Rogers4, A. Atreja4, M. Mahajan3, A. Stojmirovic5, J. Perrigoue5, C. Brodmerkel5, S. Plevy5, J. Friedman5, J-F. Colombel4, M. Dubinsky4, B. Sands4, E. Schadt3, A. Kasarskis3, B. Losic3, C. Argmann3, M. Suarez-Farinas1,3

1Icahn School at Mount Sinai, Department of Population, Health Science and Policy, New York, USA, 2University College of London, London, UK, 3Icahn School at Mount Sinai, Department of Genetics and Genomic Science, New York, USA, 4Icahn School at Mount Sinai, Department of Medicine, Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, New York City, USA, 5Janssen Research and Development, Janssen Biotech, Johnson and Johnson, Spring House, USA

OP18: Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn’s disease: the paediatric Crohn’s disease adalimumab-level-based optimisation treatment (PAILOT) trial

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Assa*1, M. Matar2, D. Turner3, E. Broide4, B. Weiss5, O. Ledder6, A. Guz Mark2, F. Rinawi2, S. Cohen7, C. Topf Olivestone8, R. Shaoul9, B. Yerushalmi10, R. Shamir2

1Schneider Children’s Hospital, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, 2Schneider Children’s medical Center, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, 3Shaare Zedek Medical Center, Gastroenterology, Nutrition and Liver Diseases, Jerusalem, Israel, 4Assaf Harofeh, Pediatric Gastroenterology, Zerifin, Israel, 5Sheba Medical Center, Pediatric Gastroenterology, Ramat Gan, Israel, 6Shaare Zedek Medical Center, Pediatric Gastroenterology, Nutrition and Liver Diseases, Jerusalem, Israel, 7Tel Aviv Medical Center, Pediatric Gastroenterology, Tel-Aviv, Israel, 8Kaplan Medical Center, Pediatric Gastroenterology, Rehovot, Israel, 9Rambam Medical center, Pediatric Gastroenterology, Haifa, Israel, 10Soroka Medical Center, Pediatric Gastroenterology, Beer Sheva, Israel

OP19: Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

Y. Haberman*1,2, R. Karns2, P. Dexheimer2, M. Schirmer3, T. Braun1, M. Collins2, A. Mo4, M. Rosen2, N. Gotman5, PROTECT Study group, S. Kugathasan6, T. D. Walters7, G. Gibson4, S. Davis Thomas5, C. Huttenhower8, R. J. Xavier9, J. S. Hyams10, L. A. Denson2

1Sheba Medical Center, Tel Hashomer, Israel, 2Cincinnati Children Hospital Medical Center, Cincinnati, USA, 3Broad Institute of MIT and Harvard University, Cambridge, USA, 4Georgia Institute of Technology, Atlanta, USA, 5University of North Carolina, Chapel Hill, USA, 6Emory University, Atlanta, USA, 7Hospital For Sick Children, Toronto, Canada, 8Harvard School of Public Health, Boston, USA, 9Broad Institute of MIT and Harvard University, Boston, USA, 10Connecticut Children’s Medical Center, Hartford, USA

OP20: Mucosal micoRNA profiles predict response to autologous stem-cell transplantation in Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Lewis*1, R. Jeffrey1, T. Kumagai1, C. J. Hawkey2, M. M. Clark2, M. Allez3, J. Satsangi4, G. Rogler5, A. Silver1, J. O. Lindsay6

1Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Genomics and Child Health, London, UK, 2Centre for Digestive Diseases, Queens Medical Centre, Nottingham, UK, 3Department of Gastroenterology, Hôpital Saint Louis, APHP, INSERM UMRS 1160, Paris Diderot, Sorbonne Paris-Cité Unversity, Paris, France, 4Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, UK, 5Department of Gastroenterology and Hepatology, University Hospital, Zurich, Switzerland, 6Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Immunobiology, London, UK

OP21: ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Vermeire1, X. Hébuterne2, P. Napora3, M. Wisniewska-Jarosinska4, G. Kiss5, A. Bourreille6, Z. Przemysław7, J. Nitcheu8, P. Gineste8, J-M. Steens*8, H. Ehrlich8

1University Hospitals Leuven, Leuven, Belgium, 2CHU Nice Hopital Archet 2, Nice, France, 3Piotr Napora Centrum Badań Klinicznych Lekarze Sp.p., Wroclaw, Poland, 4SANTA FAMILIA, Centrum Badań, Profilaktyki i Leczenia, Lodz, Poland, 5Vasútegészségügyi Nonprofit Közhasznú Kft, Debrecen, Hungary, 6CHU Nantes Hotel Dieu, Nantes, France, 7KO-Med, Lublin, Poland, 8Abivax, Paris, France

OP22: Mesenchymal stromal cell-derived exosomes stimulate epithelial regeneration in vitro and reduce experimental colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Barnhoorn*1, L. Plug1, E. Muller - de Jonge1, E. Bos2, A. van der Meulen - de Jong1, H. Verspaget1, L. Hawinkels1

1Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, The Netherlands, 2Leiden University Medical Center, Cell and Chemical Biology, Leiden, The Netherlands

OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates colitis in various animal models

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Shin*1, N. Ha1, D. Bae1, D-h. Suh1, J-y. Baek1, J. H. Jun1, Y. J. Lee1, Y. I. Choi1, K. H. Ryu1, G. S. Youn2, J. Park2, S-M. Lee3, S-k. Seo3, J. W. Lee4, J. S. Kim4,5

1Research Institute, Chong Kun Dang Pharmaceutical Corporation, Yongin, South Korea, 2Hallym University, Department of Biomedical Science, Chuncheon, South Korea, 3Inje University College of Medicine, Department of Microbiology and Immunology, Gimhae, South Korea, 4Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea, 5Seoul National University Hospital Healthcare System Gangnam Center, Department of Internal Medicine and Healthcare Research Institute, Seoul, South Korea

OP24: Effectiveness and safety of ustekinumab 90 mg every 4 weeks in Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Fumery*1, L. Peyrin-biroulet2, S. Nancey3, R. Altwegg4, P. Veyrard5, G. Bouguen6, S. Viennot7, F. Poullenot8, J. Filippi9, A. Buisson10, A. Bozon11, C. Gilletta12, F. Brazier13, L. Pouillon2, B. Flourié14, L. Boivineau4, L. Siproudhis6, D. Laharie8, X. Roblin15, X. Treton11

1Amiens University Hospital, Gastroenterology, AMIENS (80000), France, 2Nancy University Hospital, Gastroenterology, Nancy, France, 3Lyon University Hospital, Lyon, France, 4Montpellier University Hospital, Gastroenterology, Montpellier, France, 5Saint Etienne University Hospital, Gastroenterology, Saint Etienne, France, 6Rennes University Hospital, Gastroenterology, Rennes, France, 7Caen University Hospital, Gastroenterology, Caen, France, 8Bordeaux University Hospital, Gastroenterology, Bordeaux, France, 9Nice University Hospital, Gastroenterology, Nice, France, 10Clermont-Ferrand, Gastroenterology, Clermont-Ferrand, France, 11Hopital Beaujon, Gastroenterology, Clichy, France, 12Toulouse University Hospital, Gastroenterology, Toulouse, France, 13Amiens University Hospital, Gastroenterology, Amiens, France, 14Lyon University Hospital, Gastroenterology, Lyon, France, 15Saint Etienne University Hospital, Gastroenterology, Saint-Etienne, France

OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

E. Dreesen*1, F. Baert2, D. Laharie3, P. Bossuyt4, Y. Bouhnik5, A. Buisson6, G. Lambrecht7, E. Louis8, B. Oldenburg9, B. Pariente10, M. Pierik11, C. J. van der Woude12, G. D’Haens13, S. Vermeire14,15, A. Gils1

1University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, 2AZ Delta, Department of Gastroenterology, Roeselare, Belgium, 3Hôpital Haut-Lévêque, Service d’Hépato-gastroentérologie et Oncologie Digestive, Bordeaux, France, 4Imelda General Hospital, IBD Clinic, Bonheiden, Belgium, 5Beaujon Hospital, APHP, Paris Diderot University, Department of Gastroenterology, Clichy, France, 6Estaing University Hospital, Department of Gastroenterology, Clermont-Ferrand, France, 7AZ Damiaan, Department of Gastroenterology, Oostende, Belgium, 8Liège University Hospital, Department of Gastroenterology, Liège, Belgium, 9University Medical Centre, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands, 10Huriez Hospital, Lille 2 University, Department of Gastroenterology and Hepatology, Lille, France, 11University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, The Netherlands, 12Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, The Netherlands, 13Academic Medical Centre, Department of Gastroenterology, Amsterdam, The Netherlands, 14University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, 15University of Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium

OP26: Long-term safety of vedolizumab in ulcerative colitis and Crohn’s disease: final results from the GEMINI LTS study

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Vermeire1, J-F. Colombel2, B. G. Feagan3, W. J. Sandborn4, B. E. Sands2, S. Danese5, G. D’Haens6, R. Panaccione7, D. T. Rubin8, I. Shafran9, A. Parfionovas10, R. Rogers*10, R. A. Lirio10, E. V. LoftusJr11

1University Hospitals Leuven, Leuven, Belgium, 2Icahn School of Medicine at Mount Sinai, New York, USA, 3Western University, London, Canada, 4University of California San Diego, La Jolla, USA, 5Humanitas University, Milan, Italy, 6Academic Medical Centre, Amsterdam, The Netherlands, 7University of Calgary, Calgary, Canada, 8University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, USA, 9Shafran Gastroenterology Research Center, Winter Park, USA, 10Takeda Pharmaceuticals, Cambridge, USA, 11Mayo Clinic College of Medicine, Rochester, USA

OP27: High-dimensional mass cytometry reveals the immune cell landscape in inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

V. van Unen1, N. Li1, T. Abdelaal2,3, Y. Kooy-Winkelaar1, L. Ouboter*1,4, G. Beyrend1, T. Höllt3,6, L. Mearin7, A. Witte8, H. Escher9, B. Lelieveldt10,11, A. van der Meulen - de Jong4, F. Koning1

1Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, Leiden, The Netherlands, 2Delft University of Technology, Delft Bioinformatics Lab, Delft, The Netherlands, 3Leiden University Medical Center, Leiden Computational Biology Center, Leiden, The Netherlands, 4Leiden University Medical Center, Department of Gastroenterology, Leiden, The Netherlands, 6Delft University of Technology, Computer Graphics and Visualization, Delft, The Netherlands, 7Leiden University Medical Center, Department of Paediatrics, Leiden, The Netherlands, 8Alrijne Hospital, Department of Gastroenterology, Leiderdorp, The Netherlands, 9Erasmus University Medical Center, Department of Paediatric Gastroenterology, Rotterdam, The Netherlands, 10Delft University of Technology, Pattern Recognition and Bioinformatics Group, Delft, The Netherlands, 11Leiden University Medical Center, Department of LKEB Radiology, Leiden, The Netherlands

OP28: Host–microbial crosstalk in the pathogenesis of inflammation and cancer in primary sclerosing cholangitis

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Neyazi1, N. Ilott2, Oxford IBD Cohort Study Investigators1, S. Travis1, C. Arancibia1, F. Powrie2, A. Geremia*1

1Translational Gastroenterology Unit, University of Oxford, Oxford, UK, 2Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK

OP29: ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer

ECCO '19 Copenhagen

Year: 2019
Authors:

L. R. Lopetuso*1, C. De Salvo2, L. Di Martino2, W. Goodman2, F. Scaldaferri1, A. Armuzzi1, A. Gasbarrini1, T. T. Pizarro2

1Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology Gastroenterological and Oncological Area, Gastroenterological and Endocrino-Metabolical Sciences Department, Roma, Italy, 2Case Western Reserve University, Cleveland, USA

OP30: Serum proteomic profiling predicts and diagnoses pouchitis in ulcerative colitis patients undergoing ileal pouch-anal anastomosis

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Machiels*1, M. Ferrante1,2, N. Davani1, A. Wolthuis3, A. D’Hoore3, S. Vermeire1,2

1KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, 2University Hospitals Leuven, Department of gastroenterology and hepatology, Leuven, Belgium, 3University Hospitals Leuven, Abdominal surgery, Leuven, Belgium

OP31: TP53 mutation in human colonic organoids acquires resistance to in vitro long-term inflammation

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Tsuchiya*1, S. Watanabe1, T. Shirasaki1, R. Nishimura1, N. Katsukura1, S. Hibiya1, R. Okamoto1, T. Nakamura1, M. Watanabe1

1Tokyo Medical and Dental Universityl and Dental Universityl and, Tokyo, Japan

OP32: A novel mechanism of colonic epithelial-T-cell cross-talk is dysregulated in IBD

ECCO '19 Copenhagen

Year: 2019
Authors:

R. J. Dart*1,2,3, P. Vantourout1,2, P. M. Irving3, A. Hayday1,2

1King’s College London, Peter Gorer Department of Immunobiology, London, UK, 2Francis Crick Institute, Immunosurveillance Lab, London, UK, 3Guy’s and St Thomas Hospital, Department of Gastroenterology, London, UK

OP33: BUB1: a new player in the development of Crohn’s disease (CD)-associated fibrosisECCO '19 Copenhagen
Year: 2019
Authors:

V. Garlatti*1, F. Ungaro1, S. Spanò1, S. D’Alessio1,2, S. Danese1,2

1Humanitas University, Pieve Emanuele, Italy, 2Humanitas Research Hospital, Rozzano, Italy

Files: 1
OP34: VARSITY: A double-blind, double-dummy, randomised, controlled trial of vedolizumab versus adalimumab in patients with active ulcerative colitisECCO '19 Copenhagen
Year: 2019
Authors:

Stefan. Schreiber1, Laurent. Peyrin-Biroulet2, Edward. V. LoftusJr.3, Silvio. Danese4, Jean-Frederic. Colombel5, Brihad. Abhyankar6, Jingjing. Chen7, Raquel. Rogers7, Richard. A. Lirio7, Jeffrey. D. Bornstein7, Bruce. E. Sands5

1University-Hospital Schleswig-Holstein, Kiel, Germany, 2Nancy University Hospital, Nancy, France, 3Mayo Clinic College of Medicine, Rochester, MN, USA, 4Humanitas University, Milan, Italy, 5Icahn School of Medicine at Mount Sinai, NY, USA, 6Formerly Takeda Development Centre Europe Ltd, London, UK, 7Takeda Development Center Americas, Inc., Cambridge, MA, USA

OP35: Endoscopic and deep remission at 1 year prevents disease progression in early Crohn’s disease: long-term data from CALM

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Yzet1, R. Ungaro*2, P. Bossuyt3, F. Baert4, T. Vanasek5, G. D’Haens6, V. Joustra6, R. Panaccione7, G. Novacek8, A. Armuzzi9, O. Golovchenko10, O. Prymak10, A. Goldis11, S. Travis12, X. Hébuterne13, M. Ferrante14, G. Rogler15, M. Fumery1, S. Danese16, G. Rydzewska17, B. Pariente18, E. Hertervig19, C. Stanciu20, J-C. Grimaud21, M-M. Diculescu22, L. Peyrin-Biroulet23, D. Laharie24, J. P. Wright25, F. Gomollón26, I. Gubonina27, S. Schreiber28, S. Motoya29, P. Hellström30, J. Halfvarson31, J-F. Colombel2

1Amiens University Hospital, Amiens, France, 2Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, USA, 3IBD Clinic, Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium, 4AZ Delta Roeselare, Roeselare, Belgium, 52nd Department of Internal Medicine, University Hospital Hradec Králové, Hradec Králové, Czech Republic, 6Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands, 7Cumming School of Medicine, University of Calgary, Calgary, Canada, 8Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria, 9Presidio Columbus Fondazione Policlinico A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, Rome, Italy, 10Medical Clinical Investigational Center of Medical Center Health Clinic LLC, Vinnytsia, Ukraine, 11Universitatea de Medicina si Farmacie, Timisoara, Romania, 12Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, UK, 13Gastro-Entérologie and Nutrition Clinique, Hopital de l’Archet 2, Nice, France, 14University Hospitals Leuven, Leuven, Belgium, 15Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland, 16Humanitas University, Istituto Clinico Humanitas, Milan, Italy, 17Central Clinical Hospital of the Ministry of Interior in Warsaw, Warsaw, Poland, 18Claude Huriez Hospital, Lille University, Lille, France, 19Skane University Hospital, Lund, Sweden, 20Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania, 21Hepato-Gastroenterology Department, North Hospital, University of Mediterranean, Marseille, France, 22University of Medicine and Pharmacy ‘Carol Davila’, Bucharest, Romania, 23Hépato Gastro-Entérologie, Hôpital de Brabois, Nancy, France, 24Hépato-gastroentérologie et d’Oncologie Digestive, Hôpital Haut-Lévêque, Pessac, France, 25Kingsbury Hospital, Cape Town, South Africa, 26Hospital Clínico de Zaragoza, IIS Aragón, Zaragoza, Spain, 27Military Medical Academy Named After S.M.Kirov, Saint-Petersburg, Russian Federation, 28Department of Internal Medicine I, Kiel University, Kiel, Germany, 29IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan, 30Uppsala University Hospital, Uppsala, Sweden, 31Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

OP36: A colonic gene expression signature predicts non-response to anti-inflammatory therapies in inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Sato*1, K. Li1, K. Hayden1, L. Tomsho1, F. Baribaud1, C. Brodmerkel1, L. E. Greenbaum1, J. R. Friedman1, M. Curran1, Y. Imai2, S. Plevy1, S. E. Telesco1

1Janssen Research and Development, LLC, Spring House, USA, 2Janssen Pharmaceutical K.K., Tokyo, Japan